Please login to the form below

benralizumab

This page shows the latest benralizumab news and features for those working in and with pharma, biotech and healthcare.

AZ says dropping MedImmune will help ‘streamline’ its R&D

The Gaithersburg, Maryland-headquartered company is the source of a chunk of AZ’s biologics pipeline, including cancer immunotherapy Imfinzi (durvalumab) and severe asthma drug Fasenra (benralizumab) that were both highlighted

Latest news

Cancer drugs and China sustain AZ’s return to growth

Among these, severe asthma therapy Fasenra (benralizumab) shrugged off a tough competitive environment to post $297m in sales in its first full-year on the market despite going toe-to-toe
AstraZeneca wins NICE backing for asthma injection

NICE hails 'competitive pharma market'. NICE has recommended the use of AstraZeneca’s severe asthma treatment Faserna (benralizumab) after the company revised its initial pricing offer. ... Benralizumab could offer an easier method of administration
AZ says target of $45bn sales by 2023 still achievable

In respiratory, interleukin-5 inhibitor Fasenra (benralizumab) – which came to market after rival drugs from GlaxoSmithKline and Teva - is doing “extremely well”, said Soriot, capturing the lion’s share of new
Dupixent helps put Sanofi back on growth track

Fasenra (benralizumab) all jostling for market share.
FDA rejects GSK’s Nucala for COPD

Fasenra (benralizumab) and Teva’s Cinqair/Cinqaero (reslizumab).

More from news
Approximately 8 fully matching, plus 37 partially matching documents found.

Latest Intelligence

Deal Watch March 2017

In order to focus its respiratory resources on products such as Symbicort and benralizumab, AstraZeneca has agreed that its product Tudorza (marketed for COPD) and Duaklir (in phase III for COPD)
Pharma deals in July 2015

In Japan, AZ paid $45m for an option with Kyowa Hakko Kirin to commercialise benralizumab (currently in phase III for treatment of severe uncontrolled asthma and COPD) in Japan.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Project Manager - Digital Healthcare - London: Excellent Remuneration Package

Editorial / Copy Lead – Healthcare Advertising – Central London...: Salary TBC

Editorial/ Medical Director – Med Ed & Comms – Home-based...: Salary TBC

Project Manager - Medical Communications – South Wales: Excellent Remuneration Package

Senior Medical Writer: Salary TBC

Editor – Medical Education Agency – Bucks: Salary TBC

Home-based Principal Medical Writer – Medical Comms: Salary TBC

PR Associate Director – Consumer Health & Beauty: Salary TBC

Experienced / Senior Account Director - Publications - London: Up to £80, 000 plus great benefits

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Hybrid Role - Principal Medical Writer / Account Handler - Publi...: Salary TBC

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Senior Medical Writer: Competitive salary and benefits

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Director – Healthcare PR: Salary TBC

Account Manager / Senior Account Manager - Healthcare Advertisin...: Excellent Remuneration

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Senior Account Director/ Associate Director- Pharma and Life Sci...: Competitive salary and benefits

Senior / Principal Medical Writer - MedComms - Home Based / Vari...: Excellent Remuneration Packages

Senior Account Manager- Pharma and Life Scienes: Competitive salary and benefits

Account Director, Medical Education: Salary TBC

Freelance Medical Writer - Healthcare Advertising - London: Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day

Subscribe to our email news alerts

PMHub

Add my company

Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality: How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA: Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad: Six behaviours separate the good brand teams from the bad...